Novo’s newest GLP-1, CagriSema, is the first big test of Novo Nordisk’s future as the leader in the obesity treatment market.

A next-generation Novo Nordisk obesity drug designed to hit two targets has preliminary clinical data showing 22% weight loss, results that suggest the once-weekly injection could have an edge ...

The advent of GLP-1 treatments has been a game changer in the medical sector for weight loss ... time images of internal organs and soft tissues. GE HealthCare Technologies and Novo Nordisk ...

Drugmakers have poured small fortunes into the development of weight loss medicines in the past few years in attempts to lead this lucrative and fast-growing market. However, Novo Nordisk (NYSE ...

Silence can speak volumes. That silence is even louder coming from Novo Nordisk, Europe’s most valuable company, which is still reeling from disappointing weight-loss drug results in December on ...

New data suggests that the benefits of Novo Nordisk’s GLP-1 agonist semaglutide in preventing cardiovascular diseases may not simply be a result of weight loss. The analysis comes from long-term ...

Novo Nordisk (NVO) shares traded sharply higher in European trading on Friday after the Danish drugmaker said amycretin, one of its novel obesity therapies, caused up to 22% of weight loss over 36 ...

The company states: “Novo Nordisk (NVO) announced headline results ... demonstrating a statistically significant and superior weight loss at week 72 with semaglutide 7.2 mg versus placebo.

The topline results from the Phase 1b/2a clinical trial showed that patients treated with Amycretin achieved a body weight loss of 9.7% ... for Development at Novo Nordisk. "The results seen ...